These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 32228639)

  • 1. Low expression of NCALD is associated with chemotherapy resistance and poor prognosis in epithelial ovarian cancer.
    Feng LY; Li L
    J Ovarian Res; 2020 Mar; 13(1):35. PubMed ID: 32228639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NCALD affects drug resistance and prognosis by acting as a ceRNA of CX3CL1 in ovarian cancer.
    Dong C; Yin F; Zhu D; Cai X; Chen C; Liu X
    J Cell Biochem; 2020 Nov; 121(11):4470-4483. PubMed ID: 32030795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NCALD as a potential predictive biomarker for the efficacy of platinum-based chemotherapy in ovarian cancer.
    Konrad SM; Schwamborn K; Krüger A; Honert K; Schmitt M; Hellmann D; Schmalfeldt B; Meindl A; Kiechle M; Quante AS; Brambs C; Grill S; Ramser J
    Biomark Med; 2022 Oct; 16(14):1029-1041. PubMed ID: 36444691
    [No Abstract]   [Full Text] [Related]  

  • 4. Abnormal methylation characteristics predict chemoresistance and poor prognosis in advanced high-grade serous ovarian cancer.
    Feng LY; Yan BB; Huang YZ; Li L
    Clin Epigenetics; 2021 Jul; 13(1):141. PubMed ID: 34289901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High NCALD expression predicts poor prognosis of cytogenetic normal acute myeloid leukemia.
    Song Y; Zhang W; He X; Liu X; Yang P; Wang J; Hu K; Liu W; Zhang X; Jing H; Yuan X
    J Transl Med; 2019 May; 17(1):166. PubMed ID: 31109331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High expression of CETN2 is associated with platinum resistance and poor prognosis in epithelial ovarian cancer.
    Qiu PY; Deng XH; Li L
    Clin Transl Oncol; 2023 May; 25(5):1340-1352. PubMed ID: 36527574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MMP-16 as a New Biomarker for Predicting Prognosis and Chemosensitivity of Serous Ovarian Cancer: A Study Based on Bioinformatics Analysis.
    Wang W; Liu Y; Yang Y; Huang X; Hou Y
    Crit Rev Eukaryot Gene Expr; 2021; 31(4):1-8. PubMed ID: 34587431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MRPL15 is a novel prognostic biomarker and therapeutic target for epithelial ovarian cancer.
    Xu H; Zou R; Li F; Liu J; Luan N; Wang S; Zhu L
    Cancer Med; 2021 Jun; 10(11):3655-3673. PubMed ID: 33934540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive biomarkers of platinum and taxane resistance using the transcriptomic data of 1816 ovarian cancer patients.
    Fekete JT; Ősz Á; Pete I; Nagy GR; Vereczkey I; Győrffy B
    Gynecol Oncol; 2020 Mar; 156(3):654-661. PubMed ID: 31973910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
    Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
    Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
    Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
    Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition.
    Fejzo MS; Chen HW; Anderson L; McDermott MS; Karlan B; Konecny GE; Slamon DJ
    Gynecol Oncol; 2021 Feb; 160(2):539-546. PubMed ID: 33229045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD44
    Sihombing UHM; Andrijono A; Purwoto G; Gandamihardja S; Harahap AR; Rustamadji P; Kekalih A; Widyawati R; Fuady DR
    J Egypt Natl Canc Inst; 2022 Oct; 34(1):44. PubMed ID: 36274112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulation of lncRNA AB073614 functions as a predictor of epithelial ovarian cancer prognosis and promotes tumor growth in vitro and in vivo.
    Zeng S; Liu S; Feng J; Gao J; Xue F
    Cancer Biomark; 2019; 24(4):421-428. PubMed ID: 30909184
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Jeleniewicz W; Cybulski M; Nowakowski A; Stenzel-Bembenek A; Guz M; Marzec-Kotarska B; Kotarski J; Stepulak A
    Anticancer Res; 2019 Apr; 39(4):1821-1827. PubMed ID: 30952722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways.
    Nakamura K; Terai Y; Tanabe A; Ono YJ; Hayashi M; Maeda K; Fujiwara S; Ashihara K; Nakamura M; Tanaka Y; Tanaka T; Tsunetoh S; Sasaki H; Ohmichi M
    Oncol Rep; 2017 Jun; 37(6):3189-3200. PubMed ID: 28440503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian cancer risk score predicts chemo-response and outcome in epithelial ovarian carcinoma patients.
    Lu HY; Tai YJ; Chen YL; Chiang YC; Hsu HC; Cheng WF
    J Gynecol Oncol; 2021 Mar; 32(2):e18. PubMed ID: 33327048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Identification and prognostic value of differentially expressed proteins of patients with platinum resistance epithelial ovarian cancer in serum].
    Wu WJ; Wang Q; Zhang W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2016 Jul; 51(7):515-23. PubMed ID: 27465871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Annexin A8 can serve as potential prognostic biomarker and therapeutic target for ovarian cancer: based on the comprehensive analysis of Annexins.
    Gou R; Zhu L; Zheng M; Guo Q; Hu Y; Li X; Liu J; Lin B
    J Transl Med; 2019 Sep; 17(1):275. PubMed ID: 31474227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.